CAMILLERI PREZIOSI
ADVOCATES

The Secretary
Public Contracts Review Board
Notre Dame Ditch
Floriana



Camilleri Preziosi
Level 3, Valletta Buildings
South Street
Valletta, VLT 1103
Malta

(+356) 2123 8989
www.camilleripreziosi.com

30 October 2026

Reasoned Application for Remedies Before Closing

Re: ERU2710U26 MEDICINALS: Trametinib 2mg tablets, SCODE A921, 1,440 units (the "Call")

Dear Sir, Madam,

1. Introduction

1.1 We are instructed by Pharma MT Limited (C 42603) ("**Pharma MT**" or the "**Applicant**") to contest the publication and terms of the Call issued by the Central Procurement and Supplies Unit ("**CPSU**" or the "**Contracting Authority**"). The Call was published under the guise of emergency procurement, under the Emergency Procurement Regulations, S.L. 601.08 ("**EPR**")

1.2 This reasoned application seeks relief under regulation 262(1)(a) and (e) of the Public Procurement Regulations, S.L. 601.03 ("**PPR**").

2. Facts

2.1 On 26 June 2024, CT 2171/2024 was published for the supply of MEK Inhibitor Tablets/Capsules and BRAF Inhibitor Tablets/Capsules (the "**2024 Tender**"). Its estimated value was €2,970,297 excluding VAT.

2.2 On 17 July 2024, Pharma MT filed an application for remedies before closing, challenging the way the 2024 Tender was issued.

2.3 On 1 April 2025, this Board issued its decision in Case No. 2039 concerning CT 2171/2024 (the "**2024 Tender Decision**"). This Board upheld Pharma MT's complaint. It found that requiring one combination licensed for all three (3) specified indications favoured a single supplier, and that the failure to separate the indications into lots artificially narrowed competition. That decision was not appealed. The operative direction of this Board required the CPSU either to amend the existing tender into three indication-based lots or to cancel it and reissue a tender with those three lots. Under either option, quantities per lot had to be supported by clinical data and research. The CPSU failed to comply with this decision.

2.4 On 30 July 2025, the Applicant's representatives wrote to CPSU seeking information about implementation of the 2024 Tender Decision, including whether CPSU would adopt Option A or Option B and the status of any replacement tender (a copy of which is attached hereto and marked "Annex I". The letter recorded the absence, at that time, of further communications to the Applicant. No CPSU response was received, and the 2024 Tender Decisions has not been implemented.

2.5 On 10 September 2025, the Government Gazette of that date (a copy of which is attached hereto and marked "Annex II") recorded an ERU award for Dabrafenib 50mg capsules under ERU2802U25C on 7 March 2025. The Gazette list published on 6 April 2026 records another award for that strength under ERU1311U25G on 25 November 2025.

2.6 On 24 August 2026, the Government Gazette of that date (a copy of which is attached hereto and marked "Annex III") recorded an award for Trametinib 2mg tablets under ERU2601U26 and an award for Dabrafenib 75mg capsules under ERU2505U26.

2.7 On 27 October 2026, the CPSU published the Call under the EPR. The Call specifies the following product:

"Trametinib 2mg tablets"
"Trametinib dimethyl sulfoxide 2mg tablets"

The quantity is 1,440 units. The quantity field expressly states:

"UNITS (Requesting 6m stock hold - please refer to part VIII)"

The Call does not include an estimated contract value.

The deadline for submission of offer is the 2 November 2026.

3. First grievance: unlawful invocation and construction of the EPR

3.1 The scope of the EPR is to regulate emergency procurement procedures. The EPR is an exceptional regime, not a general alternative purchasing channel for all medicines.

3.2 The terms "emergency procurement" are defined in the EPR, as follows:

> *""emergency procurement" shall mean the procurement of supplies, services or works, which becomes necessary either due to an unforeseen surge in the use of supplies resulting in a month stock level, or which are otherwise necessary due to issues of national health, security or strategic importance;"*

3.3 The EPR are therefore an exception to the rule; the rule being that public procurement of products (generally) is regulated under the PPR and must comply with the processes for procurement set out therein.

3.4 The EPR cannot be used by the CPSU unless it is necessary, due to unforeseeable circumstances (such as a surge in the use of supplies resulting in a month stock level) or necessary due to issues of national health, security or strategic importance.

3.5 The EPR cannot be used for routine medicinal purchases, as this would deprive the word emergency and the regime's limited purpose of meaningful effect. The fact that a medicine treats serious disease is not, of itself, a demonstrated procurement emergency.

3.6 In addition, the EPR must also be applied consistently with binding EU procurement obligations where those obligations are engaged. The EU Directives and the PPR prohibit avoidance of the rules set out therein through valuation or unjustified subdivision and successive regular supplies.

3.7 In addition, the Treaty on the functioning of the European Union (the "**TFEU**") is applicable to all procurement, and the TFEU-based equality, non-discrimination and transparency principles are additionally material where a certain cross-border interest is established, which is the case here.

3.8 Public health remains paramount, but a justified emergency response must be distinguished from a routine six-month stock policy (which, as explained, was preceded by other calls under the EPR). If a properly designed competition could meet the need, then the EPR is not applicable. In addition, the circumstances invoked to justify the 'emergency procurement' cannot be attributable to the contracting authority.

3.9 In *Managing Consulting Service Industry (MCSI) Limited v Ministeru tal-Edukazzjoni u tal-Impjieg et*, App. Civ. 23/22/1, 4 May 2022, the Court of Appeal rejected resort to a negotiated procedure where the contracting authority had time to use competitive procedures but allowed that time to pass. It treated emergency procurement as a limited stopgap pending a regular contract, not a replacement for procurement planning (the Court also dismissed the reliance on Covid-19 as a justification for same).

3.10 *Krypton Chemists Limited v Agenzija Attiva u Kura fil-Komunità et*, App. Civ. 261/2025/1, 13 November 2025, is also particularly instructive. Essential supplies to vulnerable beneficiaries did not remove the need to substantiate extreme urgency, unforeseeability, causal connection, strict necessity and absence of fault. The Court rejected reliance on unjustified delay and deficient forward planning.

3.11 Both judgments concern the PPR negotiated-procedure derogation; they are invoked by analogy in construing the limits of the national emergency power.

3.12 The facts of this case (including previous calls and applications for remedies, such as that relating to the 2024 Tender) support the fact that there is no justification for use of the EPR, as set out in section 2 above and hereunder.

3.13 The CPSU, in June of 2024, had published the 2024 Tender, with an estimated value of €2,970,297 excluding VAT, wherein it required tenderers to supply products which were licensed for three (3) indications. At the time, only Dabrafenib and Trametinib, were licensed for all three (3) indications specified therein, which products were supplied by one supplier locally.

3.14 Other combinations, namely Vemurafenib and Cobimetinib, and Encorafenib and Binimetinib, which at the time were only licensed for one (1) or two (2) of those indications, but not all three, were therefore excluded.

3.15 Dr Nick Refalo, the Head of the Department of Oncology, testified during the hearings relating to the 2024 Tender that all product combinations referred to above were suitable. This was summarized in the 2024 Tender Decision as follows:

> *"There are three combinations of BRAF and MEK inhibitors to meet the conditions in this tender – they are all equivalent in effectiveness in treatment, but there are variations in the side effects."*

3.16 The Board, in the 2024 Tender Decision, agreed with the arguments put forward by Pharma MT, upheld the remedy before closing, and directed the Contracting Authority to either divide the 2024 Tender into lots, or to cancel the tender and publish a new one with the indications divided into lots, in each case as explained therein.

3.17 The 2024 Tender Decision was final and binding on the CPSU and the CPSU has completely discarded same and circumvented its obligations by issuing emergency procurement calls.

3.18 The Government Gazette also shows how the CPSU is engaging in a practice of using the ERU to purchase products, even where no emergency exists.

3.19 The CPSU, in breach of its obligations under Regulation 268, has sought to evade, in a systemic and repetitive manner, its legal obligations by publishing consecutive calls under the EPR, including calls:

3.19.1 Dafrabenib, 50mg capsule, awarded on 07/03/2025, for €4,444.44

3.19.2 Dafrabenib, 50mg capsule, awarded on 25/11/2025, for €8,431.49

3.19.3 Dabrafenib 50mg capsule, awarded on 03/02/2026, for €1,472.40

3.19.4 Trametinib 2mg tablets, awarded on 09/02/2026, for €130,556.40

3.19.5 Dabrafenib 75mg capsule, awarded on 02/06/2026, for €134,606.00

3.20 In addition to the list provided above, we now have this Call which, failing a favourable decision from this Board, will likewise be awarded under the EPR to the same supplier.

3.21 The CPSU has done so under the guise that such procurements - which span for more than a year from 1 April 2025 (the date of the 2024 Tender Decision) to November 2026 - constitute emergency procurements under the EPR.

3.22 The six-month stock request is also particularly material. Even a genuine immediate shortage (which is clearly not the case here) does not by itself explain why the emergency procurement must cover six months rather than the shorter interval necessary to complete a lawful competitive procurement.

3.23 The Call does not qualify as emergency procurement as defined under the EPR. It does not meet any of the constituent elements of the definition of same and has been used solely and exclusively to avoid complying with the legal obligations imposed on the CPSU under the PPR, including without limitation, Regulation 268 which is clear and unequivocal.

3.24 Without prejudice to the afore-mentioned arguments that the current Call does not comply with the constitutive elements of the definition of *"emergency procurement"* in the EPR (which concept is unique to Maltese law and has no equivalent in EU procurement law), it is also respectfully submitted that the Call (and by extension the previous calls and other similar awards by the CPSU with respect to the same drugs or active ingredients) would also, strictly by analogy, fall short of fulfilling the narrow requirements that may give rise to the justification of *"extreme urgency"* (which concept does stem from the EU Directive).

3.25 The CJEU has time and time again[1], applied the cumulative elements required for *"extreme urgency"* to subsist very narrowly, and the onus of proof lies with the Contracting Authority to prove that the exceptional procurement was provoked by:

3.25.1 an event unforeseeable by it;

3.25.2 extreme urgency caused by that event;

3.25.3 inability to meet the need through the ordinary competitive procedures, including accelerated procedures found in the Directive (transposed by the PPRs);

[1] Vide Para. 12 - Commission v. Italy, C-107/92, Para 13-14 - Commission v. Germany, C-318/94, Para. 40 - Commission v. Greece, C-394/02, Para 14-15 - Commission v. Spain, C-24/91 and Para. 22-24 - Commission v. Germany, C-126/03.

3.25.4 no conduct that may be attributable to the contracting authority has directly, or indirectly, created the circumstances relied upon; and

3.25.5 the exceptional procurement is confined to what is strictly necessary.

3.26 In addition, the Call (and previous calls) are being issued with complete disregard to the Board's decision relating to the 2024 Tender, and the testimony of the head of the Department of Oncology in those proceedings.

3.27 **In view of the above, the Applicant respectfully submits to the Board that the EPR are not applicable to the Call and that therefore the Call was published in breach of the PPR. The Applicant respectfully requests the Board to order cancellation of the Call.**

4. Second grievance: failure to implement the final 2024 Tender Decision

4.1 The 2024 Tender Decision was not appealed. In terms of Regulation 93(5) of the PPR, the decision of the Board is final and constitutes an executive title.

4.2 Regulation 93(5) PPR states:

> *"Unless there is an appeal, the **decision of the Review Board shall be final** and shall constitute an executive title and may be enforced in terms of article 273 of the Code of Organization and Civil Procedure." [emphasis added]*

4.3 Regulation 268 PPR further states:

> *"The contracting authority shall **abide by the decision of the Public Contracts Review Board in the shortest time possible** and where the contracting authority fails to implement the decision of the Public Contracts Review Board the latter may report the matter to the Minister responsible for that contracting authority." [emphasis added]*

4.4 No appeal was filed and therefore the 2024 Tender Decision is final and enforceable.

4.5 Its operative direction was not an invitation to consider three lots if convenient. The Board directed either amendment into three indication-based lots or cancellation and reissue on that basis, with supported clinical data and research determining quantities. CPSU cannot elect to do none of the two, or treat cancellation alone, followed by an indefinite series of purchases preserving the same exclusionary outcome, as implementation of a direction requiring cancellation and reissue.

4.6 The present Call purchases one component of the combination favoured by the earlier bundled specification. The Applicant submits that a six-month, molecule-

specific call, is solely intended to maintain in practice the exclusion that the Board ordered CPSU to remove.

4.7 **The Board is respectfully requested to require CPSU to account for implementation of Case No. 2039, direct compliance within its lawful powers, and consider reporting any established non-implementation under regulation 268, without prejudice to executive-title enforcement under regulation 93(5).**

5. **Third grievance: independently unjustified exclusionary specifications**

5.1 Without prejudice to the above, the design of the Call must be assessed independently under the legal regime properly applicable to it.

5.2 As explained, the Applicant submits that the Call ought to have been issued under the PPR.

5.3 Regulation 39(3) of the PPR prohibits artificially narrowing competition and regulation 53(6) requires equal access without unjustified obstacles.

5.4 In *Krypton Chemists Limited v CPSU*, App. Civ. 538/23/1, 15 February 2024, the Court of Appeal held that subjective dishonesty, fraud or collusion need not be proved under regulation 39(3) of the PPR. Objectively unjustified exclusion of near-equivalent dressings sufficed on the evidence.

5.5 Restricting participation in the Call to suppliers of Trametinib (a patented product manufactured by Novartis and supplied locally by one supplier)

5.6 **The Board is respectfully requested to, if it does order cancellation as requested in section 3 above, order the removal of discriminatory specifications.**

6. **Fourth grievance: undisclosed estimate and immediate return of excess deposit**

6.1 Regulation 5 EPR requires the competitive call's estimated value to be less than €135,000 excluding VAT. The Call does not disclose an estimate. The Applicant requests its immediate production, the date on which it was established and the underlying quantity, price, recurrence and aggregation methodology.

6.2 The Applicant does not assert that regulation 5 expressly requires the estimate to be printed in the dossier.

6.3 The omission is however material because it obstructs scrutiny of the asserted EPR entitlement, the appropriate regime and the deposit calculation.

6.4 If, as the Applicant respectfully submits, the EPR is not applicable and the procurement should have been issued under the PPR, then the estimated contract

value had to be published, along with other information (including remedies available to the Applicant).

6.5 Since there is no estimated contract value, the Applicant is provisionally submitting a deposit of €675, being 0.50% of the maximum value of a procedure under the EPR, namely €135,000.

6.6 This is paid without admission that (a) the Call is validly subject to the EPR, (b) €135,000 is its actual estimate, or (c) a deposit is lawfully required for genuine EPR procurement.

6.7 Regulation 262(2) calculates the deposit at 0.50% of the estimated value set by the contracting authority, subject to a €50,000 maximum. Once the relevant lawful estimate is established, the Board is requested to determine the precise deposit properly retainable for these proceedings.

6.8 The Applicant expressly distinguishes two sums: the deposit lawfully due under regulation 262(2), whose ultimate refund is governed by the Board's statutory decision; and any amount paid above that lawful deposit, which is not transformed into a statutory deposit merely by being remitted together with it.

6.9 The Applicant seeks immediate reimbursement of that excess, without awaiting the merits and irrespective of the outcome, while leaving the lawful deposit intact. This has been the case in all objections before the Board where the deposit exceeded what was required in terms of the PPR (including Case 2084 – P. 4074/2021 – A Negotiated Procedure for the Procurement of a Border Control System for the Malta Police Force).

6.10 **The Board is respectfully requested to require disclosure of the estimate, immediate reimbursement of any excess, and separately order refund of the balance when determining this application.**

7. Conclusion

7.1 The Board is respectfully requested to accede to this application and:

7.1.1 Order that the Call is cancelled or, failing which, order removal of discriminatory specifications in the Call;

7.1.2 Order the CPSU to account for the implementation of Case No. 2039 and direct compliance within its lawful powers;

7.1.3 Report the CPSU's non-implementation of the 2024 Tender Decision under regulation 268;

7.1.4 Order reimbursement of the excess of the deposit immediately, and reimbursement in full of the deposit together with its decision on the merits.

7.2 This application is without prejudice to further submissions and evidence that the Applicant may be permitted to present, and to any competent judicial proceedings required to preserve its rights.

Yours faithfully,





Steve Decesare

Stefan Cutajar

Annex 1

CAMILLERI PREZIOSI
ADVOCATES

Camilleri Preziosi
Level 3, Valletta Buildings
South Street
Valletta, VLT 1103
Malta

(+356) 2123 8989
www.camilleripreziosi.com

30 July 2025

ATTN: Alison Anastasi,
Head of Procurement (Pharmaceuticals)
Central Procurement & Supplies Unit (CPSU)
UB002 San Gwann Industrial Estate,
San Gwann, SGN3000

By electronic mail only

Dear Ms. Anastasi,

We write to you on behalf of our client, Pharma.MT Limited (C42603), with reference to the Public Contracts Review Board decision dated the 1st April 2025 bearing Case Number 2039 following a call for remedies before closing filed by our client with respect to the call for tenders issued by the CPSU bearing reference number CT 2171/2024 – Supplies – Tender for the Supply of Mek Inhibitor Tablets/Capsules and BRAF Inhibitor Tablets/Capsules (the "**Contested Tender**").

The PCRB concluded and decided to uphold our client's letter of objections and contentions, and directed the CPSU to pursue one of two options, these being:

Option A

1) Divide the Contested Tender into three separate lots, one lot for each of the following indications:

    i. Unresectable or metastatic melanoma with a BRAF V600 mutation, for use in combination as per SPC
    ii. Stage III melanoma with a BRAF V600 mutation as adjuvant treatment following complete resection, for use in combination as per SPC; and
    iii. Advanced NSCLC with a BRAF V600 mutation, for use in combination as per SPC; and

2) To amend the '*Closing Date for the Call for Tenders*' to the 4 May 2025; or

Option B

1) To cancel the Contested Tender procedure and re-issue a new tender with the indications divided into three (3) separate lots, as detailed in Option A above.

The PCRB also instructed the CPSU that both options require a division of quantities per lot based on supported clinical and data research. Our client never received any further communications regarding this tender and all records of the Contested Tender were removed from the official e-Tenders website, with the sole exception of the Contract notice which remains accessible.

Our client is aware that the CPSU has issued a request for proposals relating to a direct order for a different indication of similar drugs back in April 2025, but it is not informed whether or not the CPSU has re-issued the Contested Tender in line with the recommendations made by the PCRB in its decision. Our client therefore requests the CPSU to furnish it with information regarding the status of the re-issuance of the Contested Tender.

In particular, our client is formally asking the CPSU whether:

a) It shall be taking the approach recommended by the PCRB in Option A; or
b) It shall be taking the approach recommended by the PCRB in Option B?

Furthermore, our client also seeks information regarding:

a) The status of drafting and publication of the re-issued Contested Tender (in case of Option B) including but not limited to the scheduled date of publication;
b) The status of any pre-market consultation (if any) in respect to the supply of pharmaceutical products included in the Contested Tender; and
c) In case the CPSU has decided against recommencing the procedure in line with the decision of the PCRB, the reasons behind its decision not to re-issue the tender.

You are being requested to provide the information listed above in terms of regulation 242 of the Public Procurement Regulations by not later than fifteen (15) days following the receipt of this written request.

Yours faithfully,

Av. Stefan Cutajar

Stefan Cutajar

From: Anastasi Alison at MHA - CPS <alison.anastasi@gov.mt>
Sent: Thursday, 31 July 2025 17:56
To: Stefan Cutajar
Cc: Elisa Mckenna | Pharma MT; Steve Decesare; Avv. Leon Camilleri LL.B. (Hons) M.Adv; 'Dr. Alexia J. Farrugia Zrinzo'; Sammut Monica at MHA - CPS; Gili Jacqueline at MHA - CPS; Pirotta Julia at MHA - CPS
Subject: Re: Request for Information - Pharma.MT - CT2171/2024 - Supplies - Tender for the Supply of Inhibitor Tablets/Capsules and BRAF Inhibitor Tablets/Capsules - Following PCRB decision 2039 dated 1 April 2025

Dear Dr Cutajar,

Noted

Thanks

Dr. Alison Anastasi
Head of Operations (Procurement)
CPSU

From: Stefan Cutajar <stefan.cutajar@camilleripreziosi.com>
Sent: Thursday, July 31, 2025 5:09:57 PM
To: Anastasi Alison at MHA - CPS <alison.anastasi@gov.mt>
Cc: Elisa Mckenna | Pharma MT <emckenna@pharmamt.com>; Steve Decesare <steve.decesare@camilleripreziosi.com>; Avv. Leon Camilleri LL.B. (Hons) M.Adv <leon@360legalmalta.com>; 'Dr. Alexia J. Farrugia Zrinzo' <alexia@360legalmalta.com>; Sammut Monica at MHA - CPS <monica.sammut@gov.mt>; Gili Jacqueline at MHA - CPS <jacqueline.gili.1@gov.mt>; Pirotta Julia at MHA - CPS <julia.pirotta@gov.mt>
Subject: RE: Request for Information - Pharma.MT - CT2171/2024 - Supplies - Tender for the Supply of Inhibitor Tablets/Capsules and BRAF Inhibitor Tablets/Capsules - Following PCRB decision 2039 dated 1 April 2025

CAUTION: This email originated from OUTSIDE the Government Email Infrastructure. DO NOT CLICK LINKS or OPEN attachments unless you recognise the sender and know the content is safe.

Dear Dr. Anastasi,

Thank you for your prompt reply.

It would be appreciated if you could kindly update us and keep our client in copy in case there are any further noteworthy developments.

Regards,

Stefan

Stefan Cutajar
Associate
CAMILLERI PREZIOSI
(+356) 21238989 www.camilleripreziosi.com

***Summer Notice**: Please note that our offices will be **closed every Friday** throughout August. We wish you a pleasant summer.*

From: Anastasi Alison at MHA - CPS <alison.anastasi@gov.mt>
Sent: Wednesday, 30 July 2025 20:28
To: Stefan Cutajar <stefan.cutajar@camilleripreziosi.com>
Cc: Elisa Mckenna | Pharma MT <emckenna@pharmamt.com>; Steve Decesare <steve.decesare@camilleripreziosi.com>; Avv. Leon Camilleri LL.B. (Hons) M.Adv <leon@360legalmalta.com>; 'Dr. Alexia J. Farrugia Zrinzo' <alexia@360legalmalta.com>; Sammut Monica at MHA - CPS <monica.sammut@gov.mt>; Gili Jacqueline at MHA - CPS <jacqueline.gili.1@gov.mt>; Pirotta Julia at MHA - CPS <julia.pirotta@gov.mt>
Subject: Re: Request for Information - Pharma.MT - CT2171/2024 - Supplies - Tender for the Supply of Inhibitor Tablets/Capsules and BRAF Inhibitor Tablets/Capsules - Following PCRB decision 2039 dated 1 April 2025

Dear Dr Cutajar

Situation is currently pending policy direction once CPSU asked for the new updated specifications.

CPSU has been hastening the matter and there is another scheduled meeting.

Thanks,

Dr. Alison Anastasi
Head of Operations (Procurement)
CPSU

From: Stefan Cutajar <stefan.cutajar@camilleripreziosi.com>
Sent: Wednesday, July 30, 2025 3:35 PM
To: Anastasi Alison at MHA - CPS <alison.anastasi@gov.mt>
Cc: Elisa Mckenna | Pharma MT <emckenna@pharmamt.com>; Steve Decesare <steve.decesare@camilleripreziosi.com>
Subject: Request for Information - Pharma.MT - CT2171/2024 - Supplies - Tender for the Supply of Inhibitor Tablets/Capsules and BRAF Inhibitor Tablets/Capsules - Following PCRB decision 2039 dated 1 April 2025

CAUTION: This email originated from OUTSIDE the Government Email Infrastructure. DO NOT CLICK LINKS or OPEN attachments unless you recognise the sender and know the content is safe.

Dear Mr. Anastasi,

I trust this email finds you well.

I am emailing on behalf of our client Pharma.MT, in relation to the tender in caption.

Please find attached our client's request for information letter for your kind attention.

Sincerely,

Stefan

Stefan Cutajar
Associate

CAMILLERI PREZIOSI

(+356) 21238989 www.camilleripreziosi.com

Annex 11

Nru./No. 21,504
Prezz/Price
€6.66

Gazzetta tal-Gvern ta' Malta
The Malta Government Gazette

L-Erbgħa, 10 ta' Settembru, 2025
Wednesday, 10th September, 2025

Pubblikata b'Awtorità
Published by Authority

SOMMARJU – SUMMARY

Notifikazzjonijiet tal-Gvern ..... 12,081 - 12,085
Government Notices ..... *12,081 - 12,085*

Avviżi tal-Gvern ..... 12,086 - 12,221
Notices ..... *12,086 - 12,221*

Avviżi tal-Qorti ..... 12,222 - 12,224
Court Notices ..... *12,222 - 12,224*

Nru ta' Referenza tas-Sejħa Kompetittiva *Competitive Call Reference Number*	Titlu/Suġġett tas-Sejħa Kompetittiva *Title/Subject of Competitive Call*	Data tal-Għotja *Award Date*	Isem il-Kuntrattur *Contractor's Name*	Ammont tal-Kuntratt eskluża l-VAT *Contract Value Excluding VAT*
ERU1902U25A DEVICES	Sutures - Prolene Sz 3-0, L120cm Sh Blue Prolene Sz 3-0, L120cm Sh W8534	04/03/2025	A.M. Mangion Ltd	€511.20
ERU2502U25G - MEDICINAL	Potassium Iodide 65mg Eq To 50mg Iodine Tablet	04/03/2025	Pharma Regulatory Services Ltd	€124.15
ERU2502U25F - MEDICINAL	Ajmaline 50mg/10ml Injection Solution	04/03/2025	Pharma Regulatory Services Ltd	€996.00
ERU2502U25H - MEDICINAL	Thiotepa 15mg Inf Conc, Powder	04/03/2025	Cherubino Ltd	€6,400.00
ERU2502U25J - MEDICINAL	Goserelin 3.6mg Implant	04/03/2025	NM Pharma	€19,140.00
ERU2502U25A - MEDICINAL	Zoledronic Acid 5mg(100ml) Infusion Solution	04/03/2025	V.J. Salomone Pharma Ltd	€25,760.00
ERU2602U25 - DEVICES	Sterile Bone Wax 2.5g Bone Wax 2.5gr S810 1029754 Bw810 Z046	04/03/2025	A.M. Mangion Ltd	€537.60
ERU2502U25D - MEDICINAL	Atorvastatin 20mg Tablet	05/03/2025	Farmarosib SRL	€20,866.44
ERU2002U25K - DEVICES	Connecting Cable For Electrode Handle 3mm Long	05/03/2025	Associated Equipment Ltd	€2,247.00
ERU2702U25C - MEDICINAL	Trimetazidine Dihydrochloride 20mg Tablet	05/03/2025	Qualium Farma	€16,458.00
ERU2502U25I - MEDICINAL	Goserelin 10.8mg Implant	06/03/2025	Europharma Ltd	€134,850.00
ERU2502U25E - MEDICINAL	Vincristine Sulphate 2mg(2ml) Injection Iv	06/03/2025	Pharmabart Ltd	€14,715.50
ERU2802U25J MEDICINALS	Baclofen 50?G(1ml) Injection Sol It	06/03/2025	Pharma Regulatory Services Ltd	€28.80
ERU2802U25 MEDICINALS	Lanthanum 750mg Tablet Chewable	06/03/2025	Mint Health Ltd	€7,550.08
ERU2702U25B - MEDICINAL	Miconazole & Hydrocortisone 2%|1% (30g) Cream	06/03/2025	Pharmabart Ltd	€6,082.50
ERU2802U25E MEDICINALS	Temozolomide 100mg Capsule	06/03/2025	Pharma MT Ltd	€7,092.00
ERU2802U25C MEDICINALS	Dabrafenib 50mg Capsule	07/03/2025	V.J. Salomone Pharma Ltd	€4,444.44
ERU2802U25G MEDICINALS	Oral Iron Preparation 25-45mg/5m Oral Solution	07/03/2025	Pharma Regulatory Services Ltd	€4,100.40
ERU2802U25F MEDICINALS	Mitomycin C 2mg Inj Sol, Powder	07/03/2025	X Pharma	€3,808.00

CENTRAL PROCUREMENT AND SUPPLIES UNIT

Lista ta' sejħiet kompetittiva ERU mogħtija mis-Central Procurement and Supplies Unit bejn l-1 ta' Lulju, 2025 u l-31 ta' Diċembru, 2025, skont l-Artikolu 15 tar-Regolamenti tal-2016 dwar l-Akkwisti b'Emerġenża S.L.601.08.

Is-6 ta' April, 2025

Nru ta' Referenza tas-Sejħa Kompetittiva *Competitive Call Reference Number*	Titlu/Suġġett tas-Sejħa Kompetittiva *Title/Subject of Competitive Call*	Data tal-Għotja *Award Date*	Isem il-Kuntrattur *Contractor's Name*	Ammont tal-Kuntratt esklużа l-VAT *Contract Value Excluding VAT*
ERU1906U25 – MEDICINAL	Lactulose 3.335g/5ml Oral Solution	01/07/2025	V. J. Salomone Pharma Ltd	€44,766.00
ERU1306U25 – DEVICES	Disposable 5 – 11/12mm Trocar With Balloon	01/07/2025	A.M. Mangion Ltd	€1,414.00
ERU1806U25 – DEVICES	Cleaning Sanitising Wipes 20 X 25 Cm	01/07/2025	Medina Healthcare Ltd	€87,000.00
ERU2506U25A – MEDICINAL	Itraconazole 10mg/Ml(150ml) Oral Solution	01/07/2025	Pharmabart Ltd	€2,466.00
ERU2406U25A – DEVICES	Disposable Airways Iso Standard Size 8, 80mm	01/07/2025	Krypton Chemists Ltd	€1,344.60
ERU2406U25 – DEVICES	Disposable Airways Iso Standard Size 7, 70mm	01/07/2025	Krypton Chemists Ltd	€717.10
ERU2506U25D – MEDICINAL	Pyrimethamine 25mg Tablet	01/07/2025	Qualium Farma	€690.00
ERU1606U25 – DEVICES	Dual Nasal Cannula With Co2 1144001/ Flx3210125/W-0991	01/07/2025	Drugsales Ltd	€2,940.00
ERU2506U25C – MEDICINAL	Vedolizumab 300mg Inf Conc, Powder	02/07/2025	Drugsales Ltd	€127,310.00
ERU2306U25C – MEDICINAL	Selexipag 200mcg Tablets Eu/1/15/1083/002	02/07/2025	MINT Health Ltd	€21,250.00
ERU2606U25C – MEDICINAL	Flutamide 250mg Tablet	02/07/2025	Pharmabart Ltd	€3,187.80
ERU2606U25A – MEDICINAL	Upadacitinib 15mg Tablet Pro-Rel	02/07/2025	V. J. Salomone Pharma Ltd	€5,100.00
ERU2006U25 – MEDICINAL	Isosorbide Mononitrate 60mg Tablet	02/07/2025	Smartway Pharmaceuticals Limited	€33,585.76
ERU2506U25F – DEVICES	Nasal Jejunal Feeding Tube Set	02/07/2025	Charles de Giorgio Ltd	€3,920.00
ERU2306U25B – MEDICINAL	Abatacept 125mg (1ml) Inj Prefilled	02/07/2025	JV Pharma Ltd	€9,758.00
ERU2506U25E – MEDICINAL	Fluconazole 50mg/5ml(35ml) Oral Suspension	02/07/2025	Pharmabart Ltd	€2,600.00

CENTRAL PROCUREMENT AND SUPPLIES UNIT

List of competitive call contracts awarded by the Central Procurement and Supplies Unit during the period between 1st July, 2025, and 31st December, 2025, published in terms of Regulation 15 of the Emergency Procurement Regulations S.L. 601.08.

6th April, 2026

Nru ta' Referenza tas-Sejħa Kompetittiva *Competitive Call Reference Number*	Titlu/Suġġett tas-Sejħa Kompetittiva *Title/Subject of Competitive Call*	Data tal-Għotja *Award Date*	Isem il-Kuntrattur *Contractor's Name*	Ammont tal-Kuntratt esklużа l-VAT *Contract Value Excluding VAT*
ERU1811U25A MEDICINALS	Cardioplegia Concentrate (20ml) Infusion Solution	24/11/2025	Smartway Pharmaceuticals Limited	€9,148.05
ERU1711U25A – MEDICINAL	Mometasone Furoate 0.1%W/W(30g) Ointment	24/11/2025	Associated Equipment Ltd	€6,440.00
ERU1311U25G - MEDICINAL	Dabrafenib 50mg Capsule	25/11/2025	V. J. Salomone Pharma Ltd	€8,431.49
ERU1911U25A – DEVICES	Medicine Cups W/Lid	25/11/2025	Pharma Regulatory Services Ltd	€20,866.95
ERU1711U25C – DEVICES	Solero Mw Applicator – 14cm H7877001060010	26/11/2025	Drugsales Ltd	€88,936.40
ERU1711U25C – DEVICES	Solero Mw Applicator – 19cm Ang-H7877001060020	26/11/2025	Drugsales Ltd	€38,115.60
ERU1711U25D – DEVICES	Revascularization Device 6mm X 40mm 6mm X 40mm Sfr4-6-40-10	26/11/2025	E. J. Busuttil Ltd	€135,000.00
ERU1911U25B – DEVICES	Blade Surgical 15	26/11/2025	Medsytec Engineering Ltd	€13,000.00
ERU1811U25C MEDICINALS	Insulin Degludec 100iu/Ml(3ml) Inj Pen	26/11/2025	Charles de Giorgio Ltd	€134,993.20
ERU1811U25B MEDICINALS	Heparin Sodium No Preservative 10000iu(10ml) Infusion Solution	27/11/2025	V. J. Salomone Pharma Ltd	€20,880.00
ERU1911U25 – MEDICINAL	Fluticasone Propionate 50µg/Dose(120d) Inhaler Metered-Dose	27/11/2025	Pharmabart Ltd	€38,400.00
ERU2111U25L – MEDICINAL	Peptamen Junior 500ml Oral Liquid	27/11/2025	ProHealth Ltd	€7,708.32
ERU1911U25C – MEDICINAL	Acetylcysteine 200mg/Ml Infusion Registration Number: 69657	27/11/2025	E. J. Busuttil Ltd	€29,400.00
ERU2111U25 – MEDICINAL	Doxycyline 100mg Tablet/Capsule	27/11/2025	Europharma Ltd	€3,326.40
ERU2111U25A – MEDICINAL	Labetalol Hydrochloride 100mg(20ml) Injection Solution	27/11/2025	Qualium Farma	€4,316.00
ERU1111U25A – MEDICINAL	Fluticasone Propionate 250mcg Inhaler Ma1059 00802	28/11/2025	E. J. Busuttil Ltd	€135,000.00
ERU2111U25D – MEDICINAL	Stannous Agent Labelled Cells N/A Inj Kit Diagn Iv	28/11/2025	E. J. Busuttil Ltd	€2,120.00
ERU2111U25B – MEDICINAL	Cefuroxime Sodium 250mg Injection, Powder	28/11/2025	Smartway Pharmaceuticals Limited	€1,304.76
ERU2111U25I – MEDICINAL	Sugammadex Sodium 200mg(2ml) Injection Solution	28/11/2025	Alium Medical	€1,100.00

Annex III

Nru./No. 21,707
Prezz/Price
€7.56

Gazzetta tal-Gvern ta' Malta
The Malta Government Gazette

It-Tnejn, 24 ta' Awwissu, 2026
Monday, 24th August, 2026

Pubblikata b'Awtorità
Published by Authority

SOMMARJU—SUMMARY

Notifikazzjonijiet tal-Gvern 15,453
Government Notices *15,453*

Avviżi tal-Gvern ..... 15,454 - 15,615
Notices ..... *15,454 - 15,615*

Avviżi tal-Qorti 15,616
Court Notices *15,616*

Nru ta' Referenza tas-Sejħa Kompetittiva *Competitive Call Reference Number*	Titlu/Suġġett tas-Sejħa Kompetittiva *Title/Subject of Competitive Call*	Data tal-Għotja *Award Date*	Isem il-Kuntrattur *Contractor's Name*	Ammont tal-Kuntratt eskluża l-VAT *Contract Value Excluding VAT*
ERU2801U26G – MEDICINAL	Lomustine 40mg capsule	04/02/2026	Pharmachemic Trading Agency Co. Ltd	€12,450.00
ERU2801U26D – MEDICINAL	Lenalidomide 15mg capsule	04/02/2026	Prohealth Ltd	€2,269.48
ERU2801U26C – MEDICINAL	Lenalidomide 10mg capsule	05/02/2026	E.J. Busuttil Ltd	€22,127.00
ERU3001U26 DEVICES	Hydrophilic urinary catheters ch16	05/02/2026	Krypton Chemists Ltd	€51,037.92
ERU2901U26C – MEDICINAL	[Duocal] 400g powder	05/02/2026	Pharma Regulatory Services Limited	€4,500.00
ERU3001U26C MEDICINALS	Idarubicin hydrochloride 5mg inj sol, powder	05/02/2026	Smartway Pharmaceuticals Ltd	€5,748.00
ERU2901U26 – DEVICES	Alan key for pacemakers 108984	05/02/2026	VJ Salomone Pharma Ltd	€2,496.00
ERU2601U26B – DEVICES	Aorto-iliac bare metal stents	06/02/2026	E.J. Busuttil Ltd	€47,880.00
ERU2601U26B – DEVICES	Aorto-iliac bare metal stents	06/02/2026	E.J. Busuttil Ltd	€21,060.00
ERU3001U26D MEDICINALS	Nimodipine 30mg tablet	06/02/2026	Medszo	€1,278.20
ERU2901U26E – MEDICINAL	Buprenorphine 2mg sublingual tablet	06/02/2026	Noble Healthcare Ltd	€884.45
ERU3001U26B DEVICES	Cardiac Radiofrequency Ablation (RFA) Catheters with attaching cables	06/02/2026	VJ Salomone Pharma Ltd	€12,595.50
ERU3001U26A DEVICES	Bowie dick test pack	06/02/2026	VJ Salomone Pharma Ltd	€5,096.00
ERU2101U26R – MEDICINAL	Leuprorelin acetate 3.75mg inj, powder|solv	09/02/2026	MeditPharma Ltd	€16,632.09
ERU3001U26E MEDICINALS	Doxazosin 2mg Tablets PL 49565/0005	09/02/2026	Pharma Modus Ltd	€33,719.16
ERU2801U26B – MEDICINAL	Powder for the Dietary Management of Glucose Storage Disease (GLYCOSADE)	09/02/2026	Pharma Regulatory Services Limited	€420.00
ERU2601U26 – MEDICINAL	Trametinib 2mg tablet	09/02/2026	VJ Salomone Pharma Ltd	€130,556.40
ERU0202U26C – MEDICINAL	Baclofen 50 micrograms/ml Injections for Intrathecal Use AA565/06414 78168.00.00	09/02/2026	X Pharma	€381.00
ERU0202U26E – MEDICINAL	Long Acting Muscarinic Receptor Antagonists (LAMAs) Tiogiva 18mcg inhalation powder PL 25258/0370	11/02/2026	Alium Medical	€134,998.50

Nru ta' Referenza tas-Sejħa Kompetittiva *Competitive Call Reference Number*	Titlu/Suġġett tas-Sejħa Kompetittiva *Title/Subject of Competitive Call*	Data tal-Għotja *Award Date*	Isem il-Kuntrattur *Contractor's Name*	Ammont tal-Kuntratt eskluża l-VAT *Contract Value Excluding VAT*
ERU1905U26C – MEDICINAL	Plant-based liquid food preparation 1.5 Kcal/ml (fortisip plant based 1.5 Kcal, mocha lfavour)	26/05/2026	Pharma Regulatory Services Limited	€917.25
ERU1905U26 – DEVICES	Pacemaker implantation accessories	26/05/2026	VJ Salomone Pharma Ltd	€1,580.00
ERU2105U26B DEVICES	Barrier iflm stick	27/05/2026	Cherubino Ltd	€1,120.00
ERU2105U26A DEVICES	Stockings elastic below knee medium 1 pair class ii	27/05/2026	Cherubino Ltd	€877.50
ERU2105U26 – MEDICINAL	Acetazolamide sodium 500mg inj sol, powder	27/05/2026	Mawdsley-Brooks Ltd	€3,243.20
ERU1505U26A – MEDICINAL	Cabergoline 0.5mg tablets	01/06/2026	Pharmabart Ltd	€13,027.68
ERU2705U26M – DEVICES	Povidone iodine 7.5%W/v(500ml) aqueous scrub sol	02/06/2026	George Borg Barthet Ltd	€154.80
ERU2705U26E – MEDICINAL	Acetylcysteine 5% eye drops	02/06/2026	Miller & Miller (Chemicals) Ltd	€1,010.40
ERU2705U26H – MEDICINAL	Salmeterol xinafoate 25µg/dose(120d) inhaler metered-dose	02/06/2026	Pharmachemic Trading Agency Co. Ltd	€134,999.75
ERU2705U26 – MEDICINAL	Salbutamol solution for inhalation/nebulisation pl 10949/0244 ventolin respirator solution 20ml	02/06/2026	Smartway Pharmaceuticals Ltd	€67,656.60
ERU2705U26A – MEDICINAL	Start-up neonatal pn - aqueous component 500ml infusion iv	02/06/2026	VJ Salomone Pharma Ltd	€8,148.00
ERU2505U26 – MEDICINAL	Dabrafenib 75mg capsule	02/06/2026	VJ Salomone Pharma Ltd	€134,606.00
ERU2705U26K – DEVICES	Rae preformed e.T.T's cuffed 7.5mm	03/06/2026	Associated Drug Company Ltd	€640.80
ERU2705U26D – MEDICINAL	Aciclovir 800mg tablet	03/06/2026	JV Pharma Ltd	€1,008.00
ERU2705U26I – DEVICES	Tubes endotracheal cuffed 8.5 8.5mm	03/06/2026	Krypton Chemists Ltd	€756.00
ERU2705U26F – MEDICINAL	Domperidone 1mg(1ml) oral suspension	03/06/2026	Pharmabart Ltd	€692.16
ERU2705U26L – DEVICES	Enift syringes - sz. 20ml 20ml	04/06/2026	Krypton Chemists Ltd	€5,583.60
ERU2705U26N – DEVICES	Ryles ngstrc tubes for gastric drainage - sz. 10fr 10frx110cm±10 - 120cm±10	05/06/2026	Krypton Chemists Ltd	€3,922.20
ERU2705U26G – MEDICINAL	Tolvaptan 15mg and 45 mg tablets	05/06/2026	Noble Healthcare Ltd	€23,217.60
ERU2905U26A – MEDICINAL	Pku infant formula (pku anamix infant 400g tin)	05/06/2026	Pharmadynamics Ltd	€780.00

APS BANK plc

Registration number C 2192

Address APS Centre, Tower Street B'Kara BKR 4012

Printed on 30.10.2026

Printed by ELISA MC KENNA

Outgoing Payment Order

From account	20000609193
Status	**Authorised**

Currency	EUR
Amount	675.00
To account	MT55MALT011000040001EURCMG5001H
Payment date	30.10.2026
Fee	0.00
Beneficiary name	Cashier Malta Government
Beneficiary address	.
Beneficiary address line 2	
Beneficiary address line 3	VALLETTA
Country code	MT
Ordering customer	PHARMA.MT LIMITED
OPO number	PHO-9362557
Order customer swift code	APSBMTMT
Intermediary bank swift code	
Correspondent BIC	
Beneficiary swift code	MALTMTMTXXX
Value date	2026-10-30
Beneficiary bank	CENTRAL BANK OF MALTA
Exchange rate	1
Details line 1	CASE NO 2039 CT2171/2024
Details line 2	
Details line 3	
Details Line 4	